Sarepta Therapeutics, Inc. (SRPT) Analysts See $-0.32 EPS

April 16, 2018 - By Winifred Garcia

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) LogoInvestors sentiment decreased to 1.22 in 2017 Q4. Its down 1.66, from 2.88 in 2017Q3. It turned negative, as 27 investors sold Sarepta Therapeutics, Inc. shares while 67 reduced holdings. 45 funds opened positions while 70 raised stakes. 52.88 million shares or 2.28% more from 51.70 million shares in 2017Q3 were reported.
Sg Americas holds 0% of its portfolio in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) for 2,434 shares. Qvt Lp, New York-based fund reported 17,231 shares. Tiaa Cref Inv Management Ltd Co reported 0.01% of its portfolio in Sarepta Therapeutics, Inc. (NASDAQ:SRPT). Tourbillon Partners Lp has invested 1.91% in Sarepta Therapeutics, Inc. (NASDAQ:SRPT). Ontario – Canada-based Td Asset Management Inc has invested 0% in Sarepta Therapeutics, Inc. (NASDAQ:SRPT). Emerald Mutual Fund Advisers Trust has 1.55% invested in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) for 701,228 shares. Shell Asset Management stated it has 0.01% of its portfolio in Sarepta Therapeutics, Inc. (NASDAQ:SRPT). Oak Ridge Llc holds 0.49% of its portfolio in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) for 183,091 shares. State Board Of Administration Of Florida Retirement holds 0% or 33,539 shares. 714,172 are held by Northern Tru Corporation. Polar Cap Limited Liability Partnership invested in 0.01% or 25,000 shares. The New York-based Prelude Mgmt has invested 0.16% in Sarepta Therapeutics, Inc. (NASDAQ:SRPT). Australia-based Macquarie Grp Ltd has invested 0% in Sarepta Therapeutics, Inc. (NASDAQ:SRPT). Driehaus Capital Mgmt Limited has invested 0.17% in Sarepta Therapeutics, Inc. (NASDAQ:SRPT). L And S holds 8,535 shares or 0.07% of its portfolio.

Analysts expect Sarepta Therapeutics, Inc. (NASDAQ:SRPT) to report $-0.32 EPS on April, 26.They anticipate $0.41 EPS change or 56.16 % from last quarter’s $-0.73 EPS. After having $-0.37 EPS previously, Sarepta Therapeutics, Inc.’s analysts see -13.51 % EPS growth. The stock decreased 1.96% or $1.58 during the last trading session, reaching $79.22. About 493,369 shares traded. Sarepta Therapeutics, Inc. (NASDAQ:SRPT) has risen 149.90% since April 16, 2017 and is uptrending. It has outperformed by 138.35% the S&P500.

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Ratings Coverage

Among 15 analysts covering Sarepta Therapeutics (NASDAQ:SRPT), 13 have Buy rating, 0 Sell and 2 Hold. Therefore 87% are positive. Sarepta Therapeutics had 25 analyst reports since October 17, 2017 according to SRatingsIntel. As per Friday, January 19, the company rating was maintained by Leerink Swann. Piper Jaffray maintained the stock with “Buy” rating in Friday, February 9 report. The rating was maintained by Barclays Capital on Thursday, October 26 with “Equal-Weight”. The firm has “Buy” rating by SunTrust given on Thursday, March 15. JP Morgan maintained Sarepta Therapeutics, Inc. (NASDAQ:SRPT) on Wednesday, February 21 with “Overweight” rating. The stock of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) earned “Overweight” rating by Morgan Stanley on Tuesday, March 6. The firm earned “Buy” rating on Thursday, October 26 by Piper Jaffray. Leerink Swann maintained Sarepta Therapeutics, Inc. (NASDAQ:SRPT) on Tuesday, March 13 with “Outperform” rating. The stock of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) earned “Buy” rating by Piper Jaffray on Friday, March 2. The stock of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) earned “Buy” rating by Piper Jaffray on Monday, March 12.

Sarepta Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery and development of RNA therapeutics for the treatment of rare neuromuscular diseases. The company has market cap of $5.15 billion. The firm offers EXONDYS 51, a disease-modifying therapy for the treatment of duchenne muscular dystrophy , which is a rare genetic muscle-wasting disease caused by the absence of dystrophin. It currently has negative earnings. It also develops SRP-4045 and SRP-4053, which are exon skipping clinical product candidates for the treatment of DMD.

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.